<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03095521</url>
  </required_header>
  <id_info>
    <org_study_id>TE_004_ANG_LOZ</org_study_id>
    <nct_id>NCT03095521</nct_id>
  </id_info>
  <brief_title>A Local Clinical Study for the Comparative Evaluation of Efficacy and Safety of Angal, Lozenges [Menthol] and ANTI-ANGIN® FORMULA, Lozenges, in Treatment of Patients With a Sore Throat</brief_title>
  <official_title>A Prospective, Multi-center, Open, Randomized Clinical Study in Parallel Groups, for the Comparative Evaluation of Efficacy and Safety of Angal, Lozenges [Menthol], 1 mg + 5 mg (Sandoz d.d., Slovenia), and ANTI-ANGIN® FORMULA, Lozenges, 0,2 mg + 2 mg + 50 mg (LLC &quot;Valeant&quot;, Russia) in Treatment of Patients With Uncomplicated Acute Infectious and Inflammatory Diseases of the Pharynx, Accompanied by a Sore Throat.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate no less therapeutic efficacy and safety of the
      Angal, lozenges [Menthol], 1 mg + 5 mg (Sandoz dd, Slovenia) compared to ANTI-ANGIN® FORMULA,
      lozenges, 0,2 mg + 2 mg + 50 mg (LLC &quot;Valeant&quot;, Russia) in treatment of patients with
      uncomplicated acute infectious and inflammatory diseases of the pharynx, accompanied by a
      sore throat.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 22, 2017</start_date>
  <completion_date type="Actual">May 7, 2017</completion_date>
  <primary_completion_date type="Actual">May 7, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Without Sore Throat According to TSS Score</measure>
    <time_frame>4 days</time_frame>
    <description>TSS (Tonsillopharyngitis Severity Score) is a questionnaire for evaluation of the five following symptoms severity: pharyngalgia, difficulty in swallowing, salivation, hyperemia of pharyngeal mucosa, and body temperature increase according to a 4-point scale:
0 : no symptoms
: insignificant symptom
: moderate symptom
: significant symptom fever
0 pts : &lt;37.5 °С;
pts : 37.5 to &lt;38.5 °С;
pts : 38.5 to &lt;39.5 °С;
pts : ≥ 39.5 °С. TSS total ranges are 0-15.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>50% Reduction Tss SCORE</measure>
    <time_frame>day 4</time_frame>
    <description>Frequency of 50 % or more total score reduction by the TSS questionnaire completed by the Investigator relative to baseline in both Angal and ANTI-ANGIN FORMULA arms at visit 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in TSS Total Score</measure>
    <time_frame>baseline and day 4</time_frame>
    <description>Change from baseline in TSS total score. A negative change from baseline means an improvement.TSS (Tonsillopharyngitis Severity Score) is a questionnaire for evaluation of the five following symptoms severity: pharyngalgia, difficulty in swallowing, salivation, hyperemia of pharyngeal mucosa, and body temperature increase according to a 4-point scale:
0 : no symptoms
: insignificant symptom
: moderate symptom
: significant symptom fever
0 pts : &lt;37.5 °С;
pts : 37.5 to &lt;38.5 °С;
pts : 38.5 to &lt;39.5 °С;
pts : ≥ 39.5 °С. TSS total ranges are 0-15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days to Recovery, Defined by the Patient's Diary (Subjective Evaluation by the Patient)</measure>
    <time_frame>5 days</time_frame>
    <description>only patients for which outcomes were available were included , 111 out of 113 for Angal and 102 out of 107 for Antiangin, per protocol set</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Fully Recovered up to Day 5</measure>
    <time_frame>4 days for Angal, 5 days for AntiAngin</time_frame>
    <description>Number of participants who fully recovered up to day 5 (the outcome of a disease according to the objective evaluation by the Investigator, the total score according to the TSS questionnaire ≤ 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sore Throat Intensity by 100 mm in Visual Analogue Scale Filled in by the Patient (VAS) .</measure>
    <time_frame>baseline, day 4</time_frame>
    <description>The VAS is a 100-mm horizontal line on which the patient's pain intensity is represented by a point between the extremes of &quot;no pain at all&quot; and &quot;worst pain imaginable.&quot; The VAS ranges from 0 to 100. A decrease from baseline in the VAS score to reflect pain intensity indicates a decrease in pain intensity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">228</enrollment>
  <condition>Sore Throat</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Angal, lozenges, per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution, if this will happen earlier than 4th day of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ANTIANGIN ® FORMULA, 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution, if this will happen earlier than 5th day of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angal, lozenges [menthol],</intervention_name>
    <description>Angal, administered per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANTI-ANGIN® FORMULA</intervention_name>
    <description>0,2 mg + 2 mg + 50 mg (LLC &quot;Valeant&quot;, Russia). Administered per 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution.</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntarily signed informed consent for participation in this clinical study; 18 to 45
             years old inclusive, male and female;

          -  Diagnosed uncomplicated acute infectious and inflammatory diseases of the pharynx,
             accompanied by a sore throat;

          -  Onset of first symptoms of the uncomplicated acute infectious and inflammatory
             diseases of the pharynx (pharyngitis and/or tonsillitis) less than 48 hours prior to
             inclusion into the study;

          -  Baseline TSS score (Tonsillopharyngitis Severity Score) ≥ 5 (total score);

        Exclusion Criteria:

          -  Use of analgesics within &lt;12 hours prior to the study start or/and inability to cancel
             them during the study;

          -  Use of antibiotics within &lt;48 hours prior to the study start or/and inability to
             cancel them during the study;

          -  Use of local therapy (sprays, rinses, lozenges) to pharynx within &lt;12 hours before
             study start or/and inability to cancel them, besides study medications.

          -  Use systemic or inhaled corticosteroids within ≤1 months prior to the study start and
             planned therapy of them during the study (besides skin means).

          -  Presence of symptoms of primary bacterial pharyngitis or secondary bacterial infection
             (including fever over 37,5 ° C, the presence of purulent raids in the throat, severe
             intoxication, leukocytosis, neutrophilia, shift leukocyte left (increasing the
             percentage of neutrophils sticks appearance younger forms of neutrophils), increased
             ESR 30 mm/hr);
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandoz</last_name>
    <role>Study Director</role>
    <affiliation>Sandoz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Arkhangel'sk</city>
        <zip>163000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>105018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>115280</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>119192</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>127015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>135215</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>188643</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196143</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197706</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>198207</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>199178</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>199226</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Stavropol'</city>
        <zip>355000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>March 21, 2017</study_first_submitted>
  <study_first_submitted_qc>March 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2017</study_first_posted>
  <results_first_submitted>May 3, 2018</results_first_submitted>
  <results_first_submitted_qc>December 14, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 22, 2019</results_first_posted>
  <last_update_submitted>December 14, 2018</last_update_submitted>
  <last_update_submitted_qc>December 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Angal</keyword>
  <keyword>ANTI-ANGIN® FORMULA</keyword>
  <keyword>sore throat</keyword>
  <keyword>no less therapeutic efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharyngitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 28, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT03095521/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT03095521/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial included a screening period, up to 5 days active treatment, and follow-up visit. The patients had to visit the trial site up to 3 times.</recruitment_details>
      <pre_assignment_details>228 patients in total were included</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ANGAL</title>
          <description>Patients received Angal, lozenges, per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution, if happened earlier than 4th day of treatment.</description>
        </group>
        <group group_id="P2">
          <title>ANTIANGIN</title>
          <description>Patients received ANTIANGIN ® FORMULA, 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution, if happened earlier than 5th day of treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent to Treat Population ITT</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per Protocol Population PP</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ANGAL</title>
          <description>Patients received Angal, lozenges, per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution, if happened earlier than 4th day of treatment.</description>
        </group>
        <group group_id="B2">
          <title>ANTIANGIN</title>
          <description>Patients received ANTIANGIN ® FORMULA, 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution, if happened earlier than 5th day of treatment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="115"/>
            <count group_id="B2" value="113"/>
            <count group_id="B3" value="228"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>ITT</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.44" lower_limit="18" upper_limit="51"/>
                    <measurement group_id="B2" value="30.02" lower_limit="18" upper_limit="45"/>
                    <measurement group_id="B3" value="30.23" lower_limit="18" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="228"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Without Sore Throat According to TSS Score</title>
        <description>TSS (Tonsillopharyngitis Severity Score) is a questionnaire for evaluation of the five following symptoms severity: pharyngalgia, difficulty in swallowing, salivation, hyperemia of pharyngeal mucosa, and body temperature increase according to a 4-point scale:
0 : no symptoms
: insignificant symptom
: moderate symptom
: significant symptom fever
0 pts : &lt;37.5 °С;
pts : 37.5 to &lt;38.5 °С;
pts : 38.5 to &lt;39.5 °С;
pts : ≥ 39.5 °С. TSS total ranges are 0-15.</description>
        <time_frame>4 days</time_frame>
        <population>ITT, only patients with measurements were included (115 for Angal, and 112 for Antiangin)</population>
        <group_list>
          <group group_id="O1">
            <title>ANGAL</title>
            <description>Patients received Angal, lozenges, per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution, if happened earlier than 4th day of treatment.</description>
          </group>
          <group group_id="O2">
            <title>ANTIANGIN</title>
            <description>Patients received ANTIANGIN ® FORMULA, 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution, if happened earlier than 5th day of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Without Sore Throat According to TSS Score</title>
          <description>TSS (Tonsillopharyngitis Severity Score) is a questionnaire for evaluation of the five following symptoms severity: pharyngalgia, difficulty in swallowing, salivation, hyperemia of pharyngeal mucosa, and body temperature increase according to a 4-point scale:
0 : no symptoms
: insignificant symptom
: moderate symptom
: significant symptom fever
0 pts : &lt;37.5 °С;
pts : 37.5 to &lt;38.5 °С;
pts : 38.5 to &lt;39.5 °С;
pts : ≥ 39.5 °С. TSS total ranges are 0-15.</description>
          <population>ITT, only patients with measurements were included (115 for Angal, and 112 for Antiangin)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sore throat TSS score 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.35"/>
                    <measurement group_id="O2" value="73.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sore throat TSS score 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.91"/>
                    <measurement group_id="O2" value="17.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sore throat TSS score 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74"/>
                    <measurement group_id="O2" value="8.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sore throat TSS score 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Arm Angal, Arm Antiangin</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>two-sided 95% CIs estimation used to confirm non-inferior efficacy in primary endpoint. A non-inferiority conclusion was made relating to the primary parameter only.</non_inferiority_desc>
            <p_value>0.028</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>50% Reduction Tss SCORE</title>
        <description>Frequency of 50 % or more total score reduction by the TSS questionnaire completed by the Investigator relative to baseline in both Angal and ANTI-ANGIN FORMULA arms at visit 2</description>
        <time_frame>day 4</time_frame>
        <population>PP set was considered for the analysis, however only the number of patients with complete data at visit 2 were considered for the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ANGAL</title>
            <description>Patients received Angal, lozenges, per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution, if happened earlier than 4th day of treatment.</description>
          </group>
          <group group_id="O2">
            <title>ANTIANGIN</title>
            <description>Patients received ANTIANGIN ® FORMULA, 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution, if happened earlier than 5th day of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>50% Reduction Tss SCORE</title>
          <description>Frequency of 50 % or more total score reduction by the TSS questionnaire completed by the Investigator relative to baseline in both Angal and ANTI-ANGIN FORMULA arms at visit 2</description>
          <population>PP set was considered for the analysis, however only the number of patients with complete data at visit 2 were considered for the analysis</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.35" lower_limit="92.44" upper_limit="99.45"/>
                    <measurement group_id="O2" value="98.13" lower_limit="93.41" upper_limit="99.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in TSS Total Score</title>
        <description>Change from baseline in TSS total score. A negative change from baseline means an improvement.TSS (Tonsillopharyngitis Severity Score) is a questionnaire for evaluation of the five following symptoms severity: pharyngalgia, difficulty in swallowing, salivation, hyperemia of pharyngeal mucosa, and body temperature increase according to a 4-point scale:
0 : no symptoms
: insignificant symptom
: moderate symptom
: significant symptom fever
0 pts : &lt;37.5 °С;
pts : 37.5 to &lt;38.5 °С;
pts : 38.5 to &lt;39.5 °С;
pts : ≥ 39.5 °С. TSS total ranges are 0-15.</description>
        <time_frame>baseline and day 4</time_frame>
        <population>PP</population>
        <group_list>
          <group group_id="O1">
            <title>ANGAL</title>
            <description>Patients received Angal, lozenges, per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution, if happened earlier than 4th day of treatment.</description>
          </group>
          <group group_id="O2">
            <title>ANTIANGIN</title>
            <description>Patients received ANTIANGIN ® FORMULA, 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution, if happened earlier than 5th day of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in TSS Total Score</title>
          <description>Change from baseline in TSS total score. A negative change from baseline means an improvement.TSS (Tonsillopharyngitis Severity Score) is a questionnaire for evaluation of the five following symptoms severity: pharyngalgia, difficulty in swallowing, salivation, hyperemia of pharyngeal mucosa, and body temperature increase according to a 4-point scale:
0 : no symptoms
: insignificant symptom
: moderate symptom
: significant symptom fever
0 pts : &lt;37.5 °С;
pts : 37.5 to &lt;38.5 °С;
pts : 38.5 to &lt;39.5 °С;
pts : ≥ 39.5 °С. TSS total ranges are 0-15.</description>
          <population>PP</population>
          <units>unit on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.88" lower_limit="6.63" upper_limit="7.14"/>
                    <measurement group_id="O2" value="7.03" lower_limit="6.75" upper_limit="7.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" lower_limit="0.31" upper_limit="0.60"/>
                    <measurement group_id="O2" value="0.83" lower_limit="0.57" upper_limit="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days to Recovery, Defined by the Patient's Diary (Subjective Evaluation by the Patient)</title>
        <description>only patients for which outcomes were available were included , 111 out of 113 for Angal and 102 out of 107 for Antiangin, per protocol set</description>
        <time_frame>5 days</time_frame>
        <population>PP</population>
        <group_list>
          <group group_id="O1">
            <title>ANGAL</title>
            <description>Patients received Angal, lozenges, per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution, if happened earlier than 4th day of treatment.</description>
          </group>
          <group group_id="O2">
            <title>ANTIANGIN</title>
            <description>Patients received ANTIANGIN ® FORMULA, 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution, if happened earlier than 5th day of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Days to Recovery, Defined by the Patient's Diary (Subjective Evaluation by the Patient)</title>
          <description>only patients for which outcomes were available were included , 111 out of 113 for Angal and 102 out of 107 for Antiangin, per protocol set</description>
          <population>PP</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.75" spread="0.049"/>
                    <measurement group_id="O2" value="3.93" spread="0.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.482</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Fully Recovered up to Day 5</title>
        <description>Number of participants who fully recovered up to day 5 (the outcome of a disease according to the objective evaluation by the Investigator, the total score according to the TSS questionnaire ≤ 2)</description>
        <time_frame>4 days for Angal, 5 days for AntiAngin</time_frame>
        <population>PP</population>
        <group_list>
          <group group_id="O1">
            <title>ANGAL</title>
            <description>Patients received Angal, lozenges, per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution, if happened earlier than 4th day of treatment.</description>
          </group>
          <group group_id="O2">
            <title>ANTIANGIN</title>
            <description>Patients received ANTIANGIN ® FORMULA, 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution, if happened earlier than 5th day of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Fully Recovered up to Day 5</title>
          <description>Number of participants who fully recovered up to day 5 (the outcome of a disease according to the objective evaluation by the Investigator, the total score according to the TSS questionnaire ≤ 2)</description>
          <population>PP</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sore Throat Intensity by 100 mm in Visual Analogue Scale Filled in by the Patient (VAS) .</title>
        <description>The VAS is a 100-mm horizontal line on which the patient's pain intensity is represented by a point between the extremes of &quot;no pain at all&quot; and &quot;worst pain imaginable.&quot; The VAS ranges from 0 to 100. A decrease from baseline in the VAS score to reflect pain intensity indicates a decrease in pain intensity.</description>
        <time_frame>baseline, day 4</time_frame>
        <population>PP, participants with measure</population>
        <group_list>
          <group group_id="O1">
            <title>ANGAL</title>
            <description>Patients received Angal, lozenges, per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution, if happened earlier than 4th day of treatment.</description>
          </group>
          <group group_id="O2">
            <title>ANTIANGIN</title>
            <description>Patients received ANTIANGIN ® FORMULA, 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution, if happened earlier than 5th day of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sore Throat Intensity by 100 mm in Visual Analogue Scale Filled in by the Patient (VAS) .</title>
          <description>The VAS is a 100-mm horizontal line on which the patient's pain intensity is represented by a point between the extremes of &quot;no pain at all&quot; and &quot;worst pain imaginable.&quot; The VAS ranges from 0 to 100. A decrease from baseline in the VAS score to reflect pain intensity indicates a decrease in pain intensity.</description>
          <population>PP, participants with measure</population>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.38" spread="17.60"/>
                    <measurement group_id="O2" value="66.99" spread="18.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" spread="7.96"/>
                    <measurement group_id="O2" value="4.67" spread="10.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>change from baseline, 2 groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.072</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ANGAL</title>
          <description>Patients received Angal, lozenges, per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution, if happened earlier than 4th day of treatment.</description>
        </group>
        <group group_id="E2">
          <title>ANTIANGIN</title>
          <description>Patients received ANTIANGIN ® FORMULA, 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution, if happened earlier than 5th day of treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus Tachicardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>epigastric discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>hypoesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>red blood cell analysis abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>pharyngeal hypoesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However Novartis does not prohibit any inversdtigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Sandoz</organization>
      <phone>+41613241111</phone>
      <email>Sandoz.email@sandoz.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

